Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$0.72 - $1.86 $3 - $9
-5 Reduced 0.01%
66,199 $74,000
Q3 2021

Nov 15, 2021

BUY
$2.91 - $4.5 $15,079 - $23,319
5,182 Added 8.49%
66,204 $198,000
Q2 2021

Aug 13, 2021

SELL
$4.15 - $6.3 $1.27 Million - $1.93 Million
-305,822 Reduced 83.37%
61,022 $284,000
Q1 2021

May 12, 2021

SELL
$5.51 - $9.42 $143,882 - $245,984
-26,113 Reduced 6.65%
366,844 $2.2 Million
Q4 2020

Feb 11, 2021

BUY
$3.42 - $6.36 $40,766 - $75,811
11,920 Added 3.13%
392,957 $2.06 Million
Q3 2020

Nov 16, 2020

SELL
$2.94 - $12.43 $31,719 - $134,107
-10,789 Reduced 2.75%
381,037 $1.32 Million
Q2 2020

Aug 14, 2020

BUY
$5.28 - $9.67 $325,622 - $596,358
61,671 Added 18.68%
391,826 $3.4 Million
Q1 2020

May 14, 2020

BUY
$5.0 - $7.6 $117,905 - $179,215
23,581 Added 7.69%
330,155 $1.92 Million
Q4 2019

Feb 14, 2020

BUY
$5.99 - $8.38 $95,780 - $133,996
15,990 Added 5.5%
306,574 $2.21 Million
Q3 2019

Nov 13, 2019

BUY
$5.62 - $9.63 $269,164 - $461,219
47,894 Added 19.73%
290,584 $1.77 Million
Q2 2019

Aug 13, 2019

BUY
$7.59 - $10.21 $43,688 - $58,768
5,756 Added 2.43%
242,690 $2.31 Million
Q1 2019

May 13, 2019

BUY
$7.65 - $16.66 $51,882 - $112,988
6,782 Added 2.95%
236,934 $1.92 Million
Q4 2018

Feb 12, 2019

BUY
$10.76 - $17.25 $1.85 Million - $2.96 Million
171,696 Added 293.72%
230,152 $3.74 Million
Q3 2018

Nov 14, 2018

BUY
$14.34 - $22.97 $54,563 - $87,400
3,805 Added 6.96%
58,456 $952,000
Q2 2018

Aug 14, 2018

BUY
$12.76 - $16.94 $697,346 - $925,787
54,651 New
54,651 $823,000

Others Institutions Holding UBX

# of Institutions
1
Shares Held
4.41M
Call Options Held
0
Put Options Held
0

About Unity Biotechnology, Inc.


  • Ticker UBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,036,200
  • Market Cap $20.6M
  • Description
  • Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...
More about UBX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.